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Transfo rming growth factor-beta (TGF-beta) has been found 
in all cells examined thus far, and h as been show n to play 
an important ro le in inflammation and connective tissue 
form atio n . W e now repo rt that TGF-beta, alone o r in com-
binatio n w ith epidermal grow th fa ctor (EGF), led to a pref-
erential in crease in g lycosaminoglycan synthesis by cul-
tures of dermal fibroblas ts fro m patients w ith progressive 
sys tem ic sclerosis (PSS) w hen compared with no rmal fi-
broblas ts (f < 0.001) . Tran sforming g rowth facto r-beta 
in creased collagen synthesis to the sa m e extent in bo th P SS 
Scleroderm a, or prog ressive sys temic sclerosis (PSS), is a disease ultimately leading to extensive skin thickening and internal organ involvement from increased collagen deposition [1] . Dermal accumulation of glycosamino-glycans (GAG) occurs in the earl y and active phase of the 
disease [2,3]. Raynaud 's phenomenon and endothelial cell damage 
are a hallmark of PSS and frequently precede the other clinical 
mani festa ti ons [1] . Therefore, a unifying hypothesis to explain 
the pathogenesis ofPS S wo uld favor a role for factors from plas ma 
or platelets w hich, by inducing fibrosis, would link the vascular 
phenomena w ith the subsequent connective tissue abnormalities. 
To da te, investi gators have described Iymphokines and mono-
kines that stimulate or inhibit fibroblas t movement [4], growth 
[5,6], and protein synthesis, including collagen and GAG [7-9]. 
Well-characterized and purified gro w th fa ctors, including the 
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CPC: ce tylp yridiniu m chlo ride 
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EGF: epidermal growth fac tor 
FBS: fetal bovine serum 
GAG: glycosaminoglycans 
N RK: normal rat kidney 
PSS: progressive systemic sclerosis 
TCA: trichloroacetic acid 
TGF-beta: transforming growth fac to r-beta 
and normal fibrobl asts, whereas EGF had no stimulatory 
activity on collagen synthes is. The addition of E GF to cul-
tures incubated with TGF-beta led to a decrease in collagen 
synthesis compared with the effect seen with TGF-beta 
alone (p < 0.02). These studies suggest that TGF-beta m ay 
play an important ro le in the accumulation of connective 
tissue seen in PSS and that the combined action of multiple 
g rowth fa ctors m ay modulate the synthetic activity of hu-
m an dermal fibroblasts . ] In llest DermatoI89:100-104, 1987 
platelet-derived growth factor, have failed to selectively stimulate 
DNA or collagen synthesis by scleroderma fibroblasts [1 0]. Oth-
ers have shown PSS fibroblas ts to be as responsive as normal 
fibrobl as ts to lymphoid and platelet factors [11] . 
Transformin g growth fac tor-beta (TGF-beta) is a recently dis-
covered polypeptide that has been purified to homogeneity [1 2]. 
Initiall y identified in neoplas tic cells, T GF-beta has been found 
in all cells examined thus fa r and is now known to be a fund a-
mental regulator of many cellular processes [13] . Transforming 
gro wth fac tor-beta binds to specific cell surface receptors and acts 
on cells th rough both amocrine and paracrine modes. There is 
increasing evidence that T GF-beta plays an important role in 
inflammation [1 3, 14] and connective tissue fo rmation [15,1 6]. It 
may exert its biologic effects in concert with other growth fac tors 
and has been shown to increase cellular receptor levels for the 
epidermal growth factor (EGF) [17]. In view of these important 
biologic responses , we investigated the effect ofTGF-beta , alone 
or in combination with EGF, on the synthesis of GAG and col-
lagen by PSS and normal fibroblas ts. 
P.ATIENTS AND METHODS 
Selection of Patients All dermal fibroblas t cultures were ob-
tained from patients with PSS fulfilling the criteria described by 
the American Rheumatism Association [1 8]. We studied fibro-
blasts from patients with active and progressive disease who had 
not received any trea tment known to affect connecti ve tissue 
metabolism. Specifically, none of our patients had been treated 
with d-penicillamine, colchicine, systemic steroids, or other im-
munosuppress ive agents. After obtaining an informed consent, 
full-thi ckness skin biopsy specimens were taken for fibroblas t 
cultures from the dorsal aspect of the forea rm, midway between 
the wrist and the elbow . A health y donor matched for age, race, 
and sex of each patient with PSS underwent a biopsy at the 
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identi ca l site. In all our pat ien ts w ith PSS, the biopsy site co r-
responded to an area of induratcd and bound-down skin. 
Fibroblast Cultures and ExperiInental Condition Mono-
layer cultures of derm al fibroblasts were established by cxp lant 
cultures of the dcrmal-subd crmal portions of thc biopsy spcci-
mens, w hich werc min ced and placed in 25-cm2 fla sks (Co rning, 
Corning, N ew York). Thc tiss ue was allowed to air dry and 
attach to the plasti c surfacc afte r standin g at room tcmpcraturc 
for app rox imately 10 min . At this time, 2 ml of nutrient med ium 
consisting of Dulbccco's modified Eag lc's (D ME; GIBCO Lab-
oratories, Gra nd Island, New York) suppl cmcnted with] 0% feta l 
bovine scrum (FBS; GIBCO) , penicillin (100 U / ml), and strcp-
tomycin (100 j.Lg/m l) was gcn tl y added to the flask. C ultures wcre 
incubated at 3rC in 7% CO 2, 93% air. After outg rowth of cells 
from thc cxplants (2-3 weeks), subcultures were established by 
trypsinization of the primary cultures . T he fibroblasts were all in 
their 2nd to 4th passage at the start of th e experiments, and 
Mycop lasllla contamination was excluded in all cascs (Gen Probc, 
San D iego, Ca lifo rni a). Replicate monolayer culturcs were cs-
tablished by inocu latio n of2. 1-cI11 2 Nunc 4- well platcs (GIBCO) 
wi th 20,000 cclls/well on day O. The medium was changed on 
days 3 and 5 wi th DME and I 0% FBS. O n day 7 the cultures 
had reachcd confluence and thc medium of the expcrimelltal well s 
was replaced w ith 0.5 ml of DME and 3% FBS containing the 
experimental g rowth factors : TGF-beta, EGF, o r both TGF-bcta 
and EGF. The culturcs were prein cubated w ith the g rowth facto rs 
for 48 h before thc addition of radioactivc precursors. [n later 
experiments we m eas ured GAG synthesis after various time in-
tervals after the addition of TGF-bcta to fi brob las t cu ltures. 
GlycosaIninoglycan MeasureInents Monolaycr cultures were 
pulsed w ith 0.4 j.LC i o f('4C] g lucosaminc (N ew Eng land Nuclear, 
Boston, Massachusetts) for 24 h. At that time 0.1 ml of DME 
containing 5 m g/m l of pronase (Ca lbiochem-Behring Corp ., San 
Diego, California) was added to each well. The fibrobla sts de-
tached and ccll numbers were determined with a hemacytomcter. 
The remaining cell suspension (0.4 ml) containing both cells and 
medium, was incubated for 3 h at 50°C and centrifuged to clear. 
Carrier GAG, consisting of a 0.1 ml solution of hya luroni c acid 
(1 mg/ m l) and chondroitin sulfate (1 m g/ ml) (Sigma, St. louis , 
Missouri) , was then added to each sam ple followed by 1.0 ml of 
1 % cetylpyrid inium chloride (CPC) in 0.002 M NaSO., to pre-
cipitate GAG. The prccipitates wcrc collected on Whatman GF/F 
glass fiber filtcrs (W hatman In c., Clifton, New Jersey) . Indi vidual 
filters were washed twice w ith 0.1 % CPC in 0.5 M N aCI and 4 
times w ith distill ed water. T hey wcre placed in liquid scintillation 
countin g via ls and dri ed for 20 h in a 45°C oven. Scintill ation 
fluid (ACS, A mcrsham, Arlington Heights, Illinois) was thcn 
added and 14C mcasured by a Traco r Ana lytic (Model #6891, Elk 
Grove Vill age, Illinois). [n othcr experimcnts we ca rried out sep-
arate GAG assays on mcdia sa mples and cell pell ets. Thc resu lts 
obta ined with this mcthod for measuring GAG were confirmcd 
using a modified Carbazole (Eastman Kodak , Roches ter, N ew 
York) technique fo r uronic acid afte r precipitation of the polymcr 
[1 9]. 
Collagen MeasureInent T his was don e by a modifi ca tion (20) 
of the m ethod of Peterkofsky et al [21]. Aftcr a 48-h preincubation 
with the ex perimenta l grow th factors, ascorbic acid (25 j.Lg/ ml) 
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Figure 1. T he effect of increas ing molar concen trations ofTGF-beta on 
1' 4CJg lucosamine incorpo ratio n into GAG by normal dermal fibrobla sts. 
and beta-amino proprionitrile (20 j.Lg/ ml) wcrc added to the me-
dium (day 9 of culture). T he cultures were pulsed with [' 4C] proline 
(20 j.LCi/ well , N ew England Nuclcar) for 20 h at 37°C. T he me-
dium was then removcd and O. I -ml aliquots dispensed into mi-
crofuge tubes. D upli cate samples received 50 j.L1 collagenase (Ad-
vancc Biofacturers , Lynbrook, N ew York) or 50 j.L1 buffer alone. 
Aftcr incubation at 37°C for 2 h the samples were stored at 4°C 
un ti l process ing. For processing, 150 j.Ll of 10% tri chl oroacetic 
acid (TCA) was addcd to each tube. After ] 5 min at 4°C, the 
prccipitated protein was co llected on Whatman GF/ A filters. T he 
tubcs were rinscd using 5% TCA . T he indiv idua l filters were 
washed w ith 5% TCA, then 95% ethanol and allowed to air dry 
in sci ntillation vials ·overnight . Scintillation fluid (ACS, Amer-
sham) was added to the via ls and 14C was measured usin g a Tracor 
Anal ytic. Collagcn was expressed as dpm/ cell as well as percent 
relative collagen biosynthcsis . 
RESULTS 
Clinical Characteristics of Patients Studied T able I shows 
the clinical fcatures of the patients with PSS w hose dcrmal fi-
broblasts were studied . All the patients had act ive cutaneous dis-
easc and visceral involvement. The duration of discase was es-
tablishcd in each casc from the time that proximal cutaneous 
induration was first docum ented by a physician. 
Effect of TGF-Beta and EGF on GAG Synthesis Figure 1 
shows representative results of the fi rst experimen ts measurin g 
GAG accumulation in cultures of normal fibrob las ts in response 
to increasing concentrations of TGF-beta. T he results are ex-
prcssed as dpm of ["'Cjglucosamine/ ] 03 fibroblasts. There was a 
lincar increase in GAG synthesis as the TGF-beta concentration 
was increased from 4 pM to 0.2 nM (I' = 0.963) . T able II shows 
the results of GAG synthesis by 4 different norl11.al and PSS fi-
brob last cultures in response to TGF-beta (0.2 nM) , EGF (O.S 
nM) , or TGF-beta and EGF combincd . Thcse mo lar concentra-
ti ons of EGF and TGF-beta correspond to 5 ng of protein/ ml fo r 
Table I. C linica l Characteristics of the Patients With Progressive Systemic Sclerosis Whose Fibroblasts Wcre Studied 
Disease Viscera l Involvement 
Du ration Ra ynaud's Progressi ve 
Donor Sex/ Age (months) Pheno meno n Scleroderma Arthritis G I Lung H ea rt Kidney 
F/34 14 + + + 
2 F/53 10 + + + + 
3 F/47 4 + + + 
4 F/ 44 20 + + + + 
GI, gastrointestinal tract. 
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Table II. Stimulation of Glucosa mine Incorporat ion Into Glycosa minoglyca ns by Hum an D erm al Fibroblasts 
In corpo ration of II'C IG llIcosa minc Into G lycosamin oglyc3 1ls (dpmll 03 cells) 
Treatment 
3% FBS 
TGF-beta 0.2 nM 
EGF 0.8 nM 
TGF-bcta 0.2 nM 
+ EGF 0.8 nM 
139 :!: 20 
406 :!: 33 
382 :!: 40 
768 :!: 33 
PSS Donors 
2 3 
163 :!: 56 178 :!: 22 
672 :!: 25 669 :!: 70 
318 :!: 45 258 :!: 46 
880 :!: 48 999 :±; 67 
Results arc the mea n ± SD or dupli ca re dctcr mi n:ltions or tripli ca te wells. 
4 
211 :!: 18 
880 :!: 48 
NO 
NO 
Norm al Dono rs 
2 3 4 
184 :!: 20 195 :!: 15 133 :!: 32 22 1 :!: 16 
445 :!: 14 3 14 :!: 26 205 :!: 10 489 :!: 39 
385 :!: 61 41 8 :!: 38 239 :!: 36 N O 
715 :!: 25 660 :!: 44 443 :!: 65 NO 
PSS. prog ressive sys temic sclerosis: FBS. fetal bovine serllm: TGF-beta. transformin g growth factor-be ta: EG F. ep idermal gro wth factor: ND. not done. 
each growth factor. Transformin g growth fa cto r-beta caused a 
marked increase in GAG in all fibroblast cultures. In Fig 2 these 
data are represented as mea n percent of control [1 4C jglucosamine 
inco rporation into GAG (± SE). T he percent of contro l after the 
additi on of TGF-beta was 377 ± 28 for PSS and 197 ± 17 for 
normal fibrobl as ts (p < 0.001). This g reater effect on PSS fibro-
blas ts persisted in cultures incubated with both TGF-beta and 
EGF (552 ± 9 for PSS, 352 ± 13 for normal fibrobla sts ; p < 
0.001). T he sa me effect was noted in experim ents in w hi ch cells 
were incubated w ith the growth factors and 10% rather than 3% 
FBS (data not shown) .. The differential res ponse of PSS and nor-
mal fibrobla sts was specific fo r TGF-beta. Thus, in ag reement 
w ith the results of others [22], EGF increased synthesis of G AG 
by human derm al fibrobl as ts but the effect of EGF on PSS and 
normal fibroblast cultures w as not different (percen t contro l was 
205 ± 53 for PSS and 201 ± 15 for normal fib rob lasts) . 
Additional experim ents were done to find out w hether th e 
selective effect of TGF-beta on GAG synthesis in PSS was th e 
result of different kinetics and cell ul ar distribution of GAG ac-
cumulation . We measured GAG in separate assays in the media 
(extracelJular) and th e cell pellet (cellular). Tab le III shows that 
TGF-beta ca used a greater percent increase in the cellular portion 
of GAG (p < 0.001). Moreover, TGF-beta led to a g reater stim-
ulation of GAG sy nthesis in both the ex tracellular and cell ular 
compartment of PSS fibroblast cultures compared with normal 
fib roblasts (p < 0.001). Tab le IV shows that th e stimulati on of 
GAG by TGF-beta is optimal 24-48 h after the add ition ofTGF-
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Figure 2. The effect of TGF-beta, EGF, o r both on G AG synthesis by 
PSS (cross·itale/,el} co 1111 II lIS) and norm al (opC/l COIl/IIIIIS) fibroblasts. T he data 
arc represented as mean percent of baseline 1'4C lgllicosa minc incorpo-
ratio n (:!: SE). 
beta. At 24,48, and 72 h ofTGF-beta stimu lati on, PSS fibroblasts 
synthesized more GAG dun normal fibroblasts (p < 0.001) . 
Effect ofTGF-Beta and EGF on Collagen Synthesis Table 
V shows th e effe ct of TGF-beta, alone o r combined with EGF, 
on collagen synthesis. The TGF-beta stimulated proline inco r-
poration to the sa me extent in PSS and no rm al fibrobla st cultures . 
The percent of contro l rel at ive coll agen biosynthes is was not 
different (mea n ± SE: 209 ± 8 for PSS , 190 ± 11 fo r norm al 
fibrobla sts) . Epidermal g rowth factor alone had no effect on col-
lagen synthesis. T he add ition of EGF to cultures incubated w ith 
TGF-beta ca used a mean o f 20% decrease in coll agen synthesis 
compared w ith the results obtained with TGF-beta alone (p < 
0.02) . This effect was present in both no rm al and PSS fibroblasts. 
D ISCUSSION 
We have shown that T GF-beta g reatl y enh ances GAG synthesis 
by cultures of human dermal fibroblasts. Moreover, th e effect of 
TGF-beta on G AG synthes is, either alone o r combined w ith EGF, 
was consistently g rea ter for PSS fibroblas ts compared w ith nor-
mal fibroblasts and this sel ective response did no t occur in cultures 
incubated wi th EGF alone. T hus, TGF- beta may play an impor-
tant role in the accumula tion of GAG in PSS . 
Our ex periments indi ca te that this selective res ponse of TGF-
beta on GAG sy nthesis by PSS fibrob lasts is not the result of a 
different distribution of GAG in th e cellu lar o r extra cellular com-
ponent w hen compared w ith normal fibroblas ts. M oreover, the 
kin etics of GAG synthes is after TGF-beta stimulation appear to 
be simi lar for PSS and normal fibrobla sts. 
The combination of TGF-beta and EGF led to an additive, 
rather than a synergistic, stimulation of GAG sy nthesis. It is 
possible that the increased receptor levels of EGF observed with 
normal rat kidn ey (NRK) fibroblasts in response to TGF-beta 
may no t occur w ith human dermal fibrob las ts. N ot excl uded is 
the possibility that a lower concentration of EGF th an used in 
this stud y wo uld unm as k a synergistic effect w ith T GF-beta. We 
used th e present concentration of EGF beca use this ran ge has been 
found to be optimal for stim ul atin g GAG synthesis by human 
dermal fibrob las ts [22]. 
Although the results w ith GAG are more impressive because 
of th e selecti ve effect of TGF-beta on their synthesis by PSS 
Table III. Cellular (C) and Extracellular (EC) Synthes is of 
Glycosa minoglycans by Human Derma l Fibroblas ts 
Treatment PSS Donors N o rmal Dono rs 
With 
T GF-beta C EC C EC 
0.2 nM 243 :!: 27 157 :!: 4 141 :!: 4 98 :!: 6 
0.4 nM 319 :!: 8 177 :!: 8 188 :!: 8 128 :!: 3 
0.6 11M 333 :!: 21 166 :!: 6 160 :!: 4 11 8:!: 4 
Results expressed as mea n percent o f baseli ne l i'C lglucosa minc incorporat io n 
(:t SE) fo r 3 norm al and 3 (,S5 do no rs. 
T GF-bcta . tran sformin g growth facror-be t;] ; PSS. progress ive sys temi c sclerosis. 
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Table IV. Glycosaminoglycan Synthesis After D ifferent 
In cubation Times With TGF-beta 
0-24 h 
24-48 h 
48- 72 h 
Incorpora tion of [14C]Glucosamine Into 
Glycosa minoglycans (dpml103 cells) 
PSS Donors N ormal Donors 
TGF- beta TGF- beta 
3% FBS (0.2 nM) 3% FBS (0.2 nM) 
115 ± 6 210 ± 23 96 ± 5 152 ± 9 
187 ± 11 895 ± 56 152 ± 16 398 ± 32 
237 ± 8 697 ± 39 195 ± 17 339 ± 21 
Results arc the mean ~ SD of dupli cate determ inations of duplica te well s. 
TGF- beta. tra nsfo rmin g growth fac tor-beta; PSS. progressive sys temic sclerosis; 
FBS. fetal bov ine serum . 
fibroblasts, TGF-beta also stimulated the synthes is of collagen by 
cultures of both PSS and normal fibroblasts . The increase in col-
lagen synthesis induced by TGF-beta was not greater for PSS 
compared with normal fibroblasts. However, since we measured 
soluble collagen and did not assay labeled collagen in the cellular 
compartment, one cannot exclude that a di ffe rence in response 
for PSS and normal fibrobl asts may exist in the intracellular and 
extracellular deposition of collagen. 
It has been shown that TGF-beta leads to ca rtilage induction 
as well [23]. Therefore, T GF-beta may be a fundam ental regulator 
of connective tissue form ation in general. It may work in concert 
with other growth factors. Thus , in our studies, the add ition of 
EGF to PSS or normal fibroblas t cultures incubated with TGF-
beta caused a decrease in collagen synthesis compared w ith the 
results obtained with TGF-beta alone. Using NRK fibroblas ts, 
others have found that increasing concentrations of EGF pro-
gressively inhibit the TGF-beta-dependent stimulation of proline 
incorporation into collagen, and that this is not the result of the 
activation of an extracellular protease or collagenase by EGF [15]. 
However, EGF has been shown to lead to synthesis of a colla-
genase in human fib roblas t cultures [24] and this effect may partly 
acco unt for the decrease in collagen observed in our studies. In 
agreement w ith the work of others [25], EGF alone did not in-
crease collagen synthesis by human fibrobla sts in our experi-
ments. 
Our studies indicate that TGF- beta may modulate the synthesis 
of GAG and collagen by human dermal fibrob las ts. It is therefore 
possible that TGF-beta may have a key role in the abnormal 
accumulation of connective tissue in PSS, whether acting alone 
or, more likely, in combination w ith o ther cytokines. Progressive 
sys temic sclerosis dermal fibrob lasts do not appear to synthesize 
increased amo unts o f TGF-beta, compared with normal fibro-
blasts (A. B. Roberts , unpublished). H owever, as discussed be-
low, there are mechanisms for exposure of PSS fibrobla sts to 
greater than normal amounts of TGF-beta in vivo , particularl y 
as a result of platelet aggregation or mononucl ea r cell ac ti vation. 
It is quite intriguin g that in our experiments TGF-beta had a 
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selecti vely grea ter stimulation of GAG but not coll agen by PSS 
fibrob lasts. Glycosa minoglycans may influence the development 
of connective tiss ue either directl y or through their in teraction 
with other macrom olecules, such as collagen [26]; they are also 
very prominent in the wa ll of blood vessels in patients w ith earl y 
PSS [27] , and raised seru m hyaluronate levels have been found 
in PSS [28]. In the latter stud y, the increased serum hyaluronate 
levels were not related to serologic indicators of inflammatory 
activity, but a highly signi ficant correlation was present between 
ci rculating platelet counts and hyaluronate levels. In view of the 
ea rly accumulation of GAG observed in PSS befo re the fibrot ic 
stage occurs, our results may refl ect a pathogenic role of TGF-
beta in th is disease. Certain ly, mechanisms for exposure of dermal 
fibrobl as ts to TGF-beta from platelets can be postulated . Platelet 
agg rega tion and secretion may be greater in patients with ea rl y 
PSS [29,30] and the main source of TGF-beta in the body is 
platelets, w hi ch contain 500 tim es more TGF-beta ac tivity than 
any other tissue. On aggrega tion, platelets release TGF-beta from 
the alpha granules [31] . Endothelial cell dama ge, so prominent 
during the ea rl y phases of PSS [32,33], may cause platelet acti-
vation and release, allowing factors from platelets, such as TGF-
beta, to diffu se into the dermis and stimulate fibrobl as ts . There 
is as yet no completely reliable technique for measuring the con-
centration of TGF-beta in plas ma, alld therefore we have not 
attempted to determine this component in the plas ma of patients 
with PSS . However, other platelet components such as beta-
thromboglobulin are increased in the plas ma of these patients 
[28,33]. In experiments using [1 251]TGF-beta and normal fibro-
blas ts, we have recently found that serum from patients w ith 
active PSS blocks TGF-beta binding to its receptor to a greater 
extent than normal serum (V. Falanga, unpublished). T his might 
indica te that TGF-beta serum levels may be in creased in patients 
with PSS . 
Although platelets contain the larges t amount of TGF-beta, 
this polypeptide has been fo und in a variety of cell types, including 
activated peripheral blood mononuclear cells [34]. Moreover, TGF-
beta is present in culture supernatants conditioned by human T 
cells, and phytohemagglutinin activation resul ts in a 10- to 46-
fold increase in TGF-beta production by T cell s [14] . That mono-
nuclear cells may be at wo rk in PSS is suggested by the obser-
vation of ea rly mononuclea r cell infiltration at the site of disease 
activity [35]. Increased amounts ofTGF-beta, in addition to other 
mediators, could be released in the dermis fo llowing stimulation 
and activation of mononuclear cells. 
How these plausible mechanisms for exposure of dermal fi-
broblasts to TGF-beta in vivo apply to our data showing an 
increased responsiveness o f PSS fibroblas ts to TGF-beta in vit ro 
is specul ative at this point . It has been proposed that selection of 
fibroblas ts with a higher synthetic acti vity may occur in PSS [36]. 
Moreover, there is evidence that a dynamic selection of fibroblas ts 
may be opera ti ve during normal physiologic processes, such as 
wound healing [37]. What fac tors, if any, co uld be responsible 
for fi broblas t selection in PSS is unknown . O ur results with TGF-
beta do show that PSS fibrob lasts cl early res pond differently from 
Table V. Stimulation of Proline Incorporation Into Collagen by Hum an Dermal Fibroblasts 
Incorporation of ["'ClProline In to Collagen (d pm/ 1()' cells) 
Treatment 
3% FBS 
TGF-beta, 0.2 nM 
EGF, 0.8 nM 
TGF-beta , 0.2 nM 
+ EGF, 0.8 nM 
170 ± 28 
369 ± 39 
187 ± 21 
297 ± 28 
PSS Donors 
2 
196 ± 33 
432 ± 57 
20 1 ± 14 
329 ± 31 
Resu lts arc the mea n ± SD of duplica te determinations of tripli cate wells. 
N orm al DOllors 
3 2 
222 ± 45 238 ± 64 170 ± 49 
388 ± 11 394 ± 18 280 ± 52 
237 ± 30 228 ± 31 206 ± 17 
321 ± 22 295 ± 26 230 ± 15 
PSS. progressive systemic sclerosis; FBS. feta l bov ine serum; TGF-beta, transforming grow th factor-beta; EGF. epidermal growth factor. 
3 
171 ± 29 
427 ± 63 
162 ± 2 1 
332 ± 48 
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normal derm al fibro blasts to this po lypeptide. Whether this is a 
resu lt of an in vivo fibro blast selecti o n o r a specific property o f 
fi broblas ts in this di sease is the focus o f o ur current in ves tiga tions. 
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